Table 2 Alignment of VP3 proteins of different EV71 subgenogroups and escape mutants*.

From: Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

S

A

Q

A

G

K

G

Majority

        

50

       

60

       

70

       

80

        

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

S

A

Q

A

G

K

G

A BrCr VP3.pro

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

S

A

Q

A

G

K

G

B2 7423-MS-87 VP3.pro

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

S

A

Q

A

G

K

G

B4 5865-SIN-000009 VP3.pro

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

S

A

Q

A

G

K

G

B5_NUH0083_VP3.pro

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

S

A

Q

A

G

K

G

C2 NUH007-SIN-08-VP3.pro

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

S

A

Q

A

G

K

G

C4 yama lab strain VP3.pro

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

L

A

Q

A

G

K

G

E1 5H7 + A VP3.pro

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

L

A

Q

A

G

K

G

E2 5H7 + C2 VP3.pro

R

N

L

L

E

L

C

Q

V

E

T

I

L

E

V

N

N

V

P

T

N

A

T

S

L

M

E

R

L

R

F

P

V

L

A

Q

A

G

K

G

E3 5H7 + C4 VP3.pro

R

N

L

L

E

I

C

R

V

E

T

I

L

E

V

N

N

L

Q

S

N

E

T

T

P

M

Q

R

L

C

F

P

V

S

V

Q

S

K

T

G

CA16 U05876 VP3.pro

  1. *The escape mutations are highlighted in the red box. While the EV71 strains displayed 100% homology in the VP3 region shown above, the amino acid sequence of CVA16 was distinctly different as shown in red letters.